PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18953652-3	2009	To clarify the molecular mechanism of these effects, we examined the expression of Ras/MAPK signaling pathway-related molecules in human and canine breast cancer cell lines, and found that the level of c-Raf-1 protein was reduced by 5, 10 and 20 mM of NaPA treatments, though Ras activation was maintained.	Acecainide	252-256	mitogen-activated protein kinase 1	Canis lupus familiaris	87-91	
18953652-3	2009	To clarify the molecular mechanism of these effects, we examined the expression of Ras/MAPK signaling pathway-related molecules in human and canine breast cancer cell lines, and found that the level of c-Raf-1 protein was reduced by 5, 10 and 20 mM of NaPA treatments, though Ras activation was maintained.	Acecainide	252-256	TNF receptor associated factor 3	Homo sapiens	202-209	
18953652-4	2009	Dephosphorylation of c-Raf-1 at Serine (Ser) 259, Ser 338, and Ser 621 were also seen in NaPA-treated cells.	Acecainide	89-93	TNF receptor associated factor 3	Homo sapiens	21-28	
18953652-7	2009	Furthermore, expression of an epithelial marker, E-cadherin, was increased by NaPA treatment.	Acecainide	78-82	cadherin 1	Canis lupus familiaris	49-59	
18953652-8	2009	These results suggest that one of the molecular targets of NaPA treatment was the reduction of c-Raf-1 protein, and that its reduction results in the decrease of malignant characteristics of tumor cells through blockage of the Ras/MAPK signaling pathway.	Acecainide	59-63	TNF receptor associated factor 3	Homo sapiens	95-102	
18953652-8	2009	These results suggest that one of the molecular targets of NaPA treatment was the reduction of c-Raf-1 protein, and that its reduction results in the decrease of malignant characteristics of tumor cells through blockage of the Ras/MAPK signaling pathway.	Acecainide	59-63	mitogen-activated protein kinase 1	Canis lupus familiaris	231-235